Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nurix Therapeutics

11.64
+0.17001.48%
Volume:255.94K
Turnover:2.95M
Market Cap:887.38M
PE:-4.15
High:11.65
Open:11.54
Low:11.29
Close:11.47
Loading ...

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (Nx-5948) for the Treatment of WaldenstrÖM Macroglobulinemia

THOMSON REUTERS
·
17 Mar

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

GlobeNewswire
·
17 Mar

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
15 Mar

Nurix Therapeutics treatment of Waldenstrom macroglobulinemia gets orphan status

TIPRANKS
·
14 Mar

Press Release: Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

Dow Jones
·
14 Mar

Nurix Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
04 Mar

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
15 Feb

Truist Financial Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
03 Feb

Nurix Therapeutics Inc. : Morgan Stanley Raises Target Price to $17.00 From $16.00

THOMSON REUTERS
·
03 Feb

Nurix Therapeutics Faces Financial Risks Amid Supreme Court Regulatory Shift

TIPRANKS
·
30 Jan

Nurix Therapeutics Reports Solid Progress and Strong Pipeline

TIPRANKS
·
30 Jan

Nurix Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
30 Jan

Nurix Therapeutics’ Strategic Advancements and Promising Clinical Developments Justify Buy Rating

TIPRANKS
·
29 Jan

Nurix Therapeutics price target raised to $36 from $34 at Stifel

TIPRANKS
·
29 Jan

RBC Raises Price Target on Nurix Therapeutics to $27 From $26, Keeps Outperform, Speculative Risk

MT Newswires Live
·
29 Jan

Nurix Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
29 Jan

Nurix Therapeutics Inc : Stifel Raises Target Price to $36 From $34

THOMSON REUTERS
·
29 Jan

Positive Outlook for Nurix Therapeutics with Buy Rating Supported by Promising Clinical Activity and Strong Financial Position

TIPRANKS
·
29 Jan

Buy Rating for Nurix Therapeutics: Strong Cash Position and Upcoming Catalysts Justify $36 Price Target Despite Wider Net Loss

TIPRANKS
·
29 Jan

Nurix Therapeutics price target raised to $36 from $35 at H.C. Wainwright

TIPRANKS
·
29 Jan